与酒精有关的肝病中氧化应激调节:从中国植物药物到基于运动的干预措施
Yuting Zhu1, Yuqing Jia1, Enming Zhang1
1School of Sports Medicine and Physical Therapy, Beijing Sport University, Beijing, China.
中国植物药物通过向氧化应激 (OS) 来治疗与酒精有关的肝病 (ALD) 是有前途的. 对它们的机制的进一步研究和与运动的潜在结合可能会导致更安全,更有效的ALD疗法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 与酒精有关的肝病 (ALD) 是一种由过度饮酒驱动的慢性疾病,涉及诸如氧化应激 (OS) 等复杂机制.
- 目前的治疗方法包括戒酒和西方医学,但研究越来越多地探索ALD的传统中国植物药物.
- OS是ALD肝细胞损伤的关键因素,使其成为关键的治疗点.
研究的目的:
- 审查针对与酒精有关的肝病中氧化压力的中国植物药物.
- 在ALD中对各种草药化合物组的治疗作用进行分类和分析.
- 探索将植物疗法与体育炼整合为ALD管理的潜力.
主要方法:
- 关于中国植物药物及其对ALD氧化应激的影响的文献综述.
- 草药被分为六大类:黄类,多类,类,类,类,沙类和类.
- 植物特征,治疗作用和OS调节机制的分析.
主要成果:
- 中国的植物药物,包括黄类药物,多类药物,类药物,类药物,类药物和类药物,通过调节OS显示出治疗ALD的潜力.
- 这些草药可以改善ALD所涉及的组织学特征和信号通路.
- 身体炼表明在OS调节中与植物药物重叠的机制.
结论:
- 中国植物药物为ALD治疗提供了一个有前途的途径,主要是通过它们的抗氧化特性.
- 了解精确的机制和潜在的副作用对于优化临床使用至关重要.
- 将植物治疗与体育炼相结合,可能为ALD提供协同效益,需要进一步研究.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:37Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
相关概念视频
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Coronary Artery Disease IV: Preventive Measures
